Biota acquires antibacterial projects from two firms
This article was originally published in Scrip
Executive Summary
Biota Holdings has acquired early stage antibacterial programmes from the UK firm Prolysis and MaxThera of the US, in an effort to extend its research interests beyond antivirals and into the wider anti-infective area.